Thermo Fisher Scientific Inc. (TMO)
Why Is Thermo Fisher (TMO) Down 6.1% Since Last Earnings Report?
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Thermo Fisher Scientific Inc. (TMO) BofA Securities 2025 Healthcare Conference (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:40 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Michael Ryskin To kick things off, my name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and I'm excited to welcome everyone to Las Vegas for our Healthcare Conference 2025 edition.
Thermo Fisher: Tariffs Hit, Valuation Compensates
The macro environment has clearly deteriorated, with tariffs and U.S. policy weighing on short-term earnings. Management revised EPS down ~$1, but revenue guidance held as pricing and FX helped offset volume pressure. Tariff-related headwinds are expected to be fully mitigated by 2026 through supply chain adjustments.
Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In
Thermo Fisher's updated 2025 guidance shows a $1 EPS, or 4.2% hit from tariffs and government spending cuts. Thermo can mitigate the tariff issues by next year, as its scale gives it options to source from different locations. Despite short-term challenges, Thermo Fisher aims for 7-9% long-term sales growth, leveraging its diverse product range and strategic acquisitions.
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
Thermo Fisher Tops Q1 Estimates in 'Uncertain Macroeconomic Environment'
Thermo Fisher Scientific (TMO) shares rose Wednesday after the lab equipment and life science solutions firm reported first-quarter results above analysts' expectations.
Thermo Fisher Scientific Inc. (TMO) Q1 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q1 2025 Earnings Conference Call April 23, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President & Chief Executive Officer Stephen Williamson - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Rachel Vatnsdal - JPMorgan Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 First Quarter Conference Call. [Operator Instructions] I would like to introduce our moderator for the call, Mr.
Thermo Fisher (TMO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Beat Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.15 per share, beating the Zacks Consensus Estimate of $5.10 per share. This compares to earnings of $5.11 per share a year ago.
Stay Ahead of the Game With Thermo Fisher (TMO) Q1 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Thermo Fisher (TMO) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific And Its Real Value
Thermo Fisher Scientific shows strong fundamentals, consistent earnings growth, and solid financial health, making it a viable long-term investment. TMO's recent product expansion, including the breakthrough Krios 5 Cryo-TEM technology, is expected to drive future growth and support earnings. Valuation metrics indicate TMO is currently undervalued.
